Pfizer, Moderna, Johnson and Johnson vaccines effective against B1617 variant of COVID-19

Pfizer, Moderna, Johnson and Johnson vaccines effective against B1617 variant of COVID-19 World Health Organization classified the B1617 SARS-CoV-2 variant, which was first detected in India, as a variant of concern.

No comments:

Post a Comment